Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer by Cron, Kyle R. et al.
Proteasome Inhibitors Block DNA Repair and
Radiosensitize Non-Small Cell Lung Cancer
Kyle R. Cron1., Kaya Zhu1., Deepa S. Kushwaha1, Grace Hsieh1, Dmitry Merzon1, Jonathan Rameseder2,
Clark C. Chen3, Alan D. D’Andrea1,4, David Kozono1*
1Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 2Computational and Systems Biology,
Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 3Division of Neurosurgery, University of California San Diego, San Diego,
California, United States of America, 4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
Abstract
Despite optimal radiation therapy (RT), chemotherapy and/or surgery, a majority of patients with locally advanced non-small
cell lung cancer (NSCLC) fail treatment. To identify novel gene targets for improved tumor control, we performed whole
genome RNAi screens to identify knockdowns that most reproducibly increase NSCLC cytotoxicity. These screens identified
several proteasome subunits among top hits, including the topmost hit PSMA1, a component of the core 20 S proteasome.
Radiation and proteasome inhibition showed synergistic effects. Proteasome inhibition resulted in an 80–90% decrease in
homologous recombination (HR), a 50% decrease in expression of NF-kB-inducible HR genes BRCA1 and FANCD2, and a
reduction of BRCA1, FANCD2 and RAD51 ionizing radiation-induced foci. IkBa RNAi knockdown rescued NSCLC
radioresistance. Irradiation of mice with NCI-H460 xenografts after inducible PSMA1 shRNA knockdown markedly increased
murine survival compared to either treatment alone. Proteasome inhibition is a promising strategy for NSCLC
radiosensitization via inhibition of NF-kB-mediated expression of Fanconi Anemia/HR DNA repair genes.
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Introduction
Radiation therapy (RT) is a critical modality in the treatment of
lung cancer. It is highly effective when disease is localized, and
curative doses can be safely administered. For example, Stage I
non-small cell lung carcinomas (NSCLC) can be treated with
sufficiently high doses of ionizing radiation (IR) to yield 3-year
local control rates around 90% [1]. This is largely due to the high
biologically effective doses (BED) that can be administered to
isolated lung tumors using stereotactic body radiotherapy.
Unfortunately, only 15% of patients present with such tumors
[2]. More advanced tumors, which are significantly more
common, cannot be treated to higher BED, due to infiltration
of, or proximity to, radiosensitive structures including the lungs,
spinal cord, esophagus and heart [3]. This limitation accounts for
the higher local failure rates of around 30% [4]. Systemic agents
are therefore administered to enhance the radiation response.
Such agents include cytotoxic chemotherapeutics which them-
selves have significant dose-limiting toxicities and limited effects on
tumor control. Only a minority of tumors exhibit genetic features,
such as EGFR activating mutations [5] or EML4-ALK translo-
cations [6], that allow for targeted therapies; additional options are
needed.
Several genome-wide studies have been completed in NSCLC,
including DNA sequencing [7], copy number analysis [8] and
gene expression profiling [9]. These studies provided an unbiased
identification of the most frequent and important genetic and
epigenetic alterations among the 20–25,000 genes of the human
genome [10]. They revealed intriguing associations among genes
and clinical covariates, but were unable to directly demonstrate
cause-and-effect relationships between alterations and therapeutic
outcomes. In contrast, RNA interference (RNAi) can directly
demonstrate the effects of reduced gene expression on cell
physiology and survival [11].
Pooled short hairpin RNA (shRNA) screens, in which cancer
cells are exposed to several thousand different shRNA sequences,
averaging one gene knockdown per cell, have several compelling
features. First, the effect of stable shRNA knockdown over several
cell doublings can be explored, compared to transient transfection
of small interfering RNA (siRNA) sequences with short-lived
effects. Accordingly, shRNA expression mimics drug treatments
that are typically given over several weeks rather than days. Also,
cells harboring different shRNA sequences effectively compete
with each other within the pool as they proliferate, giving rise to
hits that yield more pronounced effects on proliferation [12].
Because radiotherapy is the mainstay of NSCLC treatment,
gene silencings that result in synergistic cytotoxicity when
combined with ionizing radiation (IR) are desirable. Many cancer
treatments are additive in nature, and are combined because they
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result in differential side effect profiles [13]. Synergistic treatments
that result in greater effects when administered concurrently,
compared to the additive effects of each treatment given
individually, may serve particularly well as radiosensitizers, since
RT delivery may be constrained to a limited volume, and side
effects may be less pronounced outside the irradiated volume.
Demonstrating the mechanism of a radiosensitizing shRNA
may also reveal biomarkers for patient selection and treatment
assessment. DNA double strand breaks (DSBs) are among the
effects of IR that best correlate with its cytotoxicity. A single
unrepaired DSB is sufficient to result in reproductive cell death via
G2 arrest or mitotic catastrophe [14]. DSBs are predominately
repaired through two pathways, homologous recombination (HR)
and non-homologous end-joining (NHEJ) [15]. Gene silencings or
small molecule inhibitors of either pathway may promote
radiosensitization.
Here we examine proteasome inhibition as a strategy for
NSCLC radiosensitization via inhibition of DNA DSB repair.
Proteasome inhibition has been explored in multiple clinical trials
enrolling NSCLC patients, with variable results. For example, a
Phase II study of 114 patients treated with bortezomib plus
gemcitabine and carboplatin as first-line treatment of advanced
NSCLC, showed a response rate of 23% and a disease control rate
(responses+stable disease) of 68%, thus warranting further studies
[16]. Bortezomib showed no activity as monotherapy in a Phase II
study of 14 patients, none of whom showed objective responses,
and three (21%) had stable disease lasting 3.4–11.5 months [17].
Based on our data, we propose that proteasome inhibitors may be
useful as radiosensitizers, given their repressive effects on NF-kB-
mediated expression of genes required for the HR pathway.
Results
Multiple Proteasome Genes are Top Hits in NSCLC whole
Genome RNAi Screens
A whole genome shRNA screen was conducted in two NSCLC
cell lines, A549 and NCI-H460. These lines share common genetic
features, including mutations in KRAS and STK11 (aka LKB1).
These mutations are found in tumors that are particularly
aggressive and resistant to therapy, and for which targeted
therapies are unavailable [18,19]. The cell lines are wild-type in
TP53 and therefore less likely, compared to mutated lines, to
exhibit genomic instability over the course of a screen spanning
multiple weeks [20]. Also, their genetic similarity, in terms of key
oncogenic and tumor suppressor genes, increases the probability
that screen hits in one line will be reproduced in the other (Table
S1).
The Hannon-Elledge library contains 74,705 distinct shRNA
sequences and targets nearly 18,000 genes [21]. After transduction
with this library and puromycin selection for stable integrants, cells
were passaged, and the relative representation of each sequence
within a pool was determined before and after twelve population
doublings. ShRNA sequences directed against genes essential for
cellular proliferation were selectively lost. 1,667 genes were the
targets of at least one shRNA sequence whose abundance
decreased by at least two-fold during passage in both cell lines
(Table S2). Multiple proteasome subunits numbered among the
hits in both cell lines, including the top hit PSMA1, a subunit of the
core 20 S proteasome [22] (Fig. 1 and Table S3).
Proteasome Inhibitors Sensitize NSCLC Cells to Radiation
The doxycycline-inducible shRNA knockdown of PSMA1 in
A549 and NCI-H460 resulted in loss of protein expression of both
PSMA1 and PSMB5, another subunit of the core 20 S proteasome
and the catalytic site of chymotrypsin-like (CTL) activity of the
proteasome [22] (Fig. 2A). This result confirms the essential role of
PSMA1 in 20 S proteasome assembly. Treatment with the small
molecule proteasome inhibitor bortezomib or PSMA1 shRNA
knockdown caused a loss of CTL activity (Fig. 2B).
Bortezomib is an active agent in vitro in NSCLC lines, including
A549 [23] and NCI-H460 [24], and it has previously demon-
strated radiosensitizing properties in preclinical studies [25]. The
ability of proteasome inhibitors to augment the effects of
fractionated radiation, a clinical method of delivering daily
radiation in small doses to minimize long-term toxicity [26], was
therefore explored. Bortezomib and fractionated radiation yielded
synergistic effects (Fig. 2C). Synergy was also observed with single-
dose radiation (Fig. S1), although the result with fractionated
radiation is more clinically relevant. This synergistic effect on cell
death was mediated at least in part by apoptosis; 2 Gy IR alone
did not induce apoptosis, while the combination of IR and
bortezomib induced significantly increased apoptosis compared to
either treatment alone (Fig. 2D).
Proteasome Inhibition Impairs Radiation-induced DNA
Double Strand Break Repair by Decreasing Homologous
Recombination
Given the synergy between proteasome inhibition and radia-
tion, we next determined whether proteasome inhibitors affect
radiation-induced DNA double strand breaks (DSBs) [26]
(Figure 3). In neutral comet assays, NSCLC cells repaired the
vast majority of DNA DSBs generated by high-dose irradiation
within one hour. In contrast, bortezomib treatment prior to
radiation significantly delayed the repair of DNA DSBs at least up
to 8 hours after irradiation (Fig. 3A–B). This persistence of DSBs
Figure 1. Knockdown of individual proteasome subunits
results in NSCLC cytotoxicity. Diagram of the 26 S proteasome
showing multiple whole genome shRNA screen hits with the following
color code: top hit (red), strong hit (.1 shRNA sequence per gene in
both cell lines, dark orange), minor hit (1 shRNA sequence per gene in
both cell lines, light orange), chymotrypsin-like proteolytic catalytic site
(not a hit but highlighted for illustrative purposes, green). Each hit is
labeled using the last two alphanumeric characters of the gene’s HUGO
nomenclature; e.g., A1 = PSMA1, B5 = PSMB5, M1= SHFM1.
doi:10.1371/journal.pone.0073710.g001
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may result in increased mitotic catastrophe [27], which is believed
to be the predominant cause of cell death in irradiated solid
malignancies.
To observe the effects of bortezomib or RNAi knockdown of
PSMA1 on DNA repair, a GFP reporter construct for HR [28] was
introduced into A549 and NCI-H460 cells. Compared to
Figure 2. Proteasome inhibition sensitizes NSCLC cells to radiation. (A) Western blot showing protein levels of PSMA1 and PSMB5 in A549
and NCI-H460 NSCLC cells after PSMA1 shRNA knockdown compared to non-silencing shRNA control. (B) Chymotrypsin-like (CTL) proteasome activity
assay in A549 (left) and NCI-H460 (right) NSCLC cells after treatment with bortezomib, or PSMA1 siRNA knockdown. All results are mean 6 SEM and
normalized to DMSO vehicle control. (C) Clonogenic survival assay of A549 (left) and NCI-H460 (right) following IR and bortezomib. Marked bars show
the percent kill of bortezomib-treated samples compared to DMSO vehicle control at each IR dose. All results are mean 6 SEM and normalized to
DMSO vehicle control. (D) Apoptosis detection assay of NCI-H460 following 2 and 4 Gy IR and 50 nM bortezomib. Bars show percentage of cells in
early apoptosis (left) or late apoptosis (right) via Annexin V and propidum iodide staining, respectively. All results are mean 6 SD and P values were
calculated using a two-tailed Student’s t test.
doi:10.1371/journal.pone.0073710.g002
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untreated cells, those treated with either bortezomib or PSMA1
siRNA showed a statistically significant decrease in HR-mediated
repair of I-SceI-induced DNA DSBs (Fig. 3C). Similar results were
observed for NHEJ (Fig. S2). These results demonstrate a direct
effect of proteasome inhibition on the mechanisms of DNA DSB
repair, consistent with previous studies [29–31].
To understand the mechanism of HR inhibition, we explored
the effect of bortezomib on nuclear focus formation of key proteins
in the Fanconi Anemia (FA)/HR pathway. IR-induced RAD51
nuclear focus formation, which is a biomarker for HR [32], was
substantially decreased by bortezomib or PSMA1 RNAi (Fig. 4A,
Fig. S3–S4). FANCD2 protein expression and IR-induced
FANCD2 focus formation were similarly decreased by bortezomib
or PSMA1 RNAi (Fig. 4B, Fig. S3–S4). Finally, IR-induced
BRCA1 focus formation was significantly decreased by bortezo-
mib or PSMA1 RNAi (Fig. 4C, Fig. S3–S4). Taken together, these
data suggest that proteasome inhibition may impact HR-mediated
repair of IR-induced DNA DSBs by reducing availability or
recruitment of key FA/HR proteins to damage sites.
Figure 3. Proteasome inhibition impairs radiation-induced DNA double strand break (DSB) repair by decreasing homologous
recombination. (A) Visualization of a neutral comet assay showing IR induced DNA DSB in NCI-H460 cells 1, 4 and 8 hours after 40 Gy IR and pre-
treated with 50 nM bortezomib compared to DMSO vehicle control. (B) Quantification of the neutral comet assay via olive moment (left) and % DNA
in tail (right) at 1, 4 and 8 hours post 40 Gy IR with and without 50 nM bortezomib in NCI-H460 cells. Each data point represents 3 independent
replicate experiments of at least 50 cells. All results are mean 6 SD and P values were calculated using a two-tailed Student’s t test. (B) GFP reporter
assay for homologous recombination after proteasome inhibition for 24 hours via bortezomib or PSMA1 siRNA knockdown in A549 (left) and NCI-
H460 (right). All results are mean6 SD and normalized to DMSO vehicle control (Veh) or nonsilencing siRNA control. P values were calculated using a
two-tailed Student’s t test.
doi:10.1371/journal.pone.0073710.g003
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Proteasome Inhibition Blocks NF-kB Induced Expression
of Fanconi Anemia/Homologous Recombination Genes
We next explored the relationship between proteasome
inhibition and the FA/HR pathway via NF-kB signaling. Dalton
and colleagues [33] previously showed that bortezomib decreases
FA/BRCA gene expression in multiple myeloma cells, and that
NF-kB transcriptionally upregulates the FA/BRCA pathway. For
instance, NF-kB binds directly to the promoter of FANCD2, based
on the electrophoretic mobility shift assay (EMSA) (Fig. 5A). One
mechanism by which bortezomib downregulates the NF-kB
pathway is through inhibition of proteasome-mediated degrada-
tion of IkBa [34]. IkBa, which sequesters NF-kB in the cytoplasm,
and phosphorylation of IkBa by the inhibitor of NF-kB kinases
(IKKs) releases NF-kB, allowing its entry to the nucleus [35].
Bortezomib also downregulates the NF-kB pathway by inducing
nuclear translocation of IkBa, resulting in suppression of NF-kB
p65/50-dependent transcription [36].
We therefore sought to determine whether the IR-induced
transcription of FA/HR genes FANCD2 and BRCA1 is diminished
by proteasome inhibition. Transcription of FANCD2 and BRCA1
increased within 30 minutes of irradiation, and was substantially
blocked by either bortezomib or PSMA1 RNAi (Fig. 5B–C). This
short time scale could account for the short-term effect on DSB
repair observed in the comet assay. To establish causality, we
performed a rescue experiment in NSCLC cells pretreated with
IkBa siRNA. Cells were then subjected to proteasome inhibition
and irradiation. IkBa knockdown rescued radioresistance and cell
survival of bortezomib-treated cells (Fig. 5D). These data establish
a role for proteasome inhibitors as radiosensitizers, via blockade of
NF-kB induced expression of FA/HR genes (Fig. 6).
Combination of Proteasome Inhibition and Radiation
Enhances Tumor Control
We next sought to determine whether proteasome inhibition
may be a useful strategy in vivo. Poor penetration of bortezomib
into tumors may limit its efficacy in solid malignancies [37]. We
therefore tested whether inducible PSMA1 RNAi knockdown
enhances control of xenografts treated with fractionated radio-
therapy (RT).
To administer fractionated RT, we used a small animal
radiation research platform (SARRP) that can deliver CT-guided
conformal RT to tumors in mice [38,39]. This platform ensures
complete treatment of the tumor while minimizing irradiation of
uninvolved tissues. It also facilitated volumetric assessments of
tumor growth and partially correlated (r = 0.61) with caliper
measurements (Fig. 7A–B).
Mice were implanted with NCI-H460 cells harboring a
doxycycline-inducible PSMA1 shRNA construct. One week after
initiation of PSMA1 knockdown, tumors were irradiated to a dose
of 20 Gy in five fractions. After RT treatments, PSMA1
knockdown was discontinued, and mice were followed for up to
100 days after tumor formation (Fig. 7C). Untreated mice showed
rapid development of tumors. Mice treated with either RT or the
inducible PSMA1 knockdown in tumor cells also showed
progressive tumor growth and poor survival. Mice treated
concurrently with both treatments however showed minimal to
no xenograft growth and 100% survival (Fig. 7D–E). IR-induced
FANCD2 focus formation was also reduced in tumor specimens
showing inducible PSMA1 knockdown (Fig. 8A). The reduction in
these foci may serve in the future as a biomarker for reduction of
IR-induced activation of FA/HR pathway following proteasome
inhibition. Significantly increased IR-induced c-H2AX foci in
tumor specimens persisted at 1, 6, and 24 hours with PSMA1
knockdown compared to control, indicating delayed DNA DSB
repair. (Fig. 8B–C).
The dramatic results observed with PSMA1 knockdown are in
contrast with those observed previously with bortezomib in vivo,
including genetically engineered mouse models (GEMMs) of lung
adenocarcinoma [40]. Given the results with PSMA1 knockdown,
the ability of bortezomib to radiosensitize NCI-H460 xenografts
was examined to determine whether there may be greater
tumoricidal effect with this combination therapy. There was no
significant difference in survival of mice treated with radiotherapy
with or without bortezomib (Figure S5). To determine whether
this was due to poor tumor drug penetration, chymotrypsin-like
proteasome activity was examined in tumors treated with or
without bortezomib compared to tumors with or without PSMA1
knockdown. There was substantially more proteasome inhibition
following PSMA1 knockdown compared to that following
bortezomib (Figure S6). This suggests that the limited efficacy
observed with bortezomib in vivo may be related to poor tumor
drug penetration, which would explain the discrepancies in results
in vitro and in vivo.
Discussion
The purpose of this study was to establish a rationale for
proteasome inhibition as a strategy for NSCLC radiosensitization.
We reasoned that since DNA double strand breaks (DSBs)
correlate with the cytotoxicity of ionizing radiation (IR) [26],
agents that delay the repair of these breaks may act as
radiosensitizers. Accordingly, we observed decreases in homolo-
gous recombination (HR) following proteasome inhibition, signif-
icant delays in DNA DSB repair both in vitro and in vivo, and
reduced levels of IR-induced expression and damage site
localization of DNA repair proteins. Proteasome inhibitors
function, at least in part, by blocking the NF-kB pathway by
interfering with degradation of IkBa, which inhibits downstream
NF-kB activity [34,35]. Bortezomib decreased the IR-induced
expression following proteasome inhibition of Fanconi Anemia
(FA)/BRCA genes, the majority of which have putative NF-kB
binding sites [33]. Importantly, we rescued bortezomib-induced
radiosensitivity by silencing IkBa, supporting the proposed
mechanism. Proteasome inhibitors therefore appear to radiosen-
sitize NSCLC by interfering with DNA DSB repair by reducing
the expression of key NF-kB-inducible HR genes.
An alternate explanation for the effects of proteasome inhibition
on radiosensitivity is through the induction of apoptosis. Multiple
studies have demonstrated an increase in apoptosis following
bortezomib treatment [41]. Apoptosis has not been shown as the
predominant mode of cell death in irradiated NSCLC. For
example, high doses such as 20 Gy irradiation of A549 or NCI-
H460 cells yield rates of apoptosis of only 5–35% [42]. NCI-H460
cells treated with both 2 Gy IR and bortezomib showed increased
apoptosis compared to either treatment alone. Of note, the
Figure 4. Proteasome inhibition impairs radiation-induced DNA double strand break repair by decreasing homologous
recombination. (A) After bortezomib624 hours or PSMA1 knockdown672 hours, A549 or NCI-H460 cells were irradiated then fixed after 6
hours. RAD51 foci were detected by immunofluorescence. Cells with $5 foci were scored as positive (n .100). All results are mean 6 SEM. P values
were calculated using a two-tailed Student’s t test. Photos show representative images for NCI-H460 treated with bortezomib, bar = 10 mm. (B) As in
(A), but for FANCD2, including Western blot and immunofluorescence. (C) As in (A), but for BRCA1.
doi:10.1371/journal.pone.0073710.g004
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persistence of DNA DSBs following irradiation of cells exposed to
proteasome inhibitors may also itself contribute to apoptosis.
We observed reduced growth of NSCLC xenografts following
proteasome inhibition combined with RT. GEMMs of lung cancer
may be used to confirm the effect in primary lung tumors treated
in situ. Exploring this in multiple GEMMs may have the additional
advantage of identifying genotypes that particularly respond to
proteasome inhibition. For instance, tumors arising from mice
harboring inducible KRAS and TP53 mutations responded to
bortezomib, unlike tumors from mice with mutant KRAS and wild-
type TP53 [40]. We observed marked differences in survival with
inducible proteasome knockdown in NSCLC xenografts express-
ing wild-type TP53, which is in contrast with these results. We
propose that the combination with radiation may unlock the
potential of proteasome inhibition to a wider range of tumor
genotypes.
The adoption of proteasome inhibitors in the clinic will require
improvement in tumor delivery. Bortezomib yielded relatively
little proteasome inhibition in our xenograft studies compared to
doxycycline-induced PSMA1 shRNA knockdown. Strategies in-
Figure 5. Proteasome inhibition blocks expression of Fanconi Anemia/Homologous Recombination genes. (A) Diagram of NF-kB
promoters on FANCD2 and BRCA1 genes. (B) Expression by qPCR of FANCD2 following proteasome inhibition 630 nM (A549) or 50 nM (NCI-H460)
bortezomib or 6 inducible PSMA1 shRNA, and 610 Gy IR. All values are normalized to ACTB and all results are mean 6 SEM. (C) As in (B) but with
BRCA1. (D) NSCLC cell survival following bortezomib and IR is partially rescued by IkBa siRNA knockdown when performed in advance. Cell viability
was assayed using an ATP luminescence-based assay measuring relative luminescent units (RLU). All results are mean 6 SEM.
doi:10.1371/journal.pone.0073710.g005
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cluding liposomal encapsulation, which has been successfully
employed for doxorubicin [43], or use of second-generation
proteasome inhibitors such as carfilzomib, marizomib or
MLN9708 [44] may improve solid tumor penetration and
proteasome inhibition.
The results of proteasome inhibition in NSCLC patients treated
without radiotherapy have been mixed [16,17]. Proteasome
inhibition was examined with concurrent chemoradiotherapy in
one Phase I trial of twelve patients [45]. In this dose escalation
study, patients with pathologically documented Stage IIIA-B
disease received weekly carboplatin and paclitaxel, together with
bortezomib 0.3–0.7 mg/m2 twice weekly, during radiotherapy to
a dose of 61.2 Gy in 34 daily fractions, followed by surgical
resection. There were no unanticipated acute toxicities during
chemoradiotherapy; Grade 2–3 myelosuppression was common,
as expected with carboplatin and paclitaxel. Regrettably however,
three of nine patients who underwent surgical resection died
postoperatively; two died two to three days postoperatively and a
third died 21 days postoperatively. It was concluded that delayed
toxicity was severe and unpredictable. However, all three patients
had undergone a right pneumonectomy after high-dose neoadju-
vant chemoradiotherapy. Right pneumonectomy following neoad-
juvant therapy has been associated with significantly increased
mortality risk, regardless of addition of novel systemic agents. For
example, there has been a reported 18% treatment-related
mortality rate after right pneumonectomy, compared to a 4%
rate after left pneumonectomy, after neoadjuvant radiotherapy to
a median dose of 54 Gy with concurrent chemotherapy [46].
What was notable about the Phase I study [45] was the high rate
of pathologic complete response (pCR) observed in patients
treated with neoadjuvant chemoradiotherapy including bortezo-
mib. Specimens from five of the nine patients (56%) who
underwent surgical resection showed a pCR and an additional
two showed 99% necrosis. This compares favorably to the 17.7%
pCR rate observed in INT-0139 following neoadjuvant chemor-
adiotherapy among the 164 patients who underwent resection
[47]. This data suggests that, with care, proteasome inhibition may
be worth exploring further combined with radical chemora-
diotherapy, perhaps in nonsurgical candidates or for left-sided or
other tumors that will not require right pneumonectomy for
resection.
Finally, proteasome inhibitors may disproportionally benefit
patients whose tumors rely on HR-mediated repair of radiation-
induced DNA DSBs. For example, high level of RAD51 protein
expression has been associated with decreased survival of NSCLC
patients [48]. Also, poorly differentiated NSCLC tumors have
increased expression of HR genes [49]. In an analysis of published
microarray data from 442 patients [9], high levels of RAD51 and
BRCA1 were each associated with decreased overall survival
(Figure S7). These features may serve as biomarkers predictive of
response to proteasome inhibitors as radiosensitizers. Also,
reductions in radiation-induced DNA DSB repair protein foci,
including FANCD2 and BRCA1, following treatment with




Bortezomib was purchased from Selleck Chemicals (Houston,
TX). 800 mM stocks in DMSO were stored at 220uC, and prior
to use were diluted and stored at 4uC for up to one week. All
treatments were at a final concentration of 30 nM for A549 or
50 nM for NCI-H460, unless stated otherwise. The following
antibodies were used at the listed dilutions for Western immuno-
blots: PSMA1 (ARP40417, Aviva Systems Biology, San Diego,
CA, 1:2000), PSMB5 (BML-PW8895, Enzo Life Sciences, Farm-
ingdale, NY, 1:1000), FANCD2 (sc-20022, Santa Cruz Biotech-
nology, Santa Cruz, CA, 1:200), vinculin (sc-25336, Santa Cruz
Biotechnology, 1:1000), anti-mouse (NA931v, GE Healthcare UK
United, Little Chalfont, Buckinghamshire, UK, 1:3000) and anti-
rabbit (NA934v, GE Healthcare UK United, 1:3000) horseradish
peroxidase-linked secondary antibodies. The following antibodies
were used at the listed dilutions for immunofluorescence: BRCA1
(sc-6954, Santa Cruz Biotechnology, 1:50), RAD51 (PC-130,
EMD Millipore, Billerica, MA, 1:1000), FANCD2 (sc-20022,
Santa Cruz Biotechnology, 1:250), Alexa Fluor anti-mouse
(4408 S, Cell Signaling Technology, 1:3000) and anti-rabbit
(4412 S, Cell Signaling Technology, 1:3000).
Cell Lines and Mice
Human NSCLC cell lines A549 and NCI-H460 were grown at
37uC in humidified 5% CO2 in Gibco RPMI 1640 (Life
Technologies, Grand Island, NY) containing 10% fetal bovine
serum (FBS, Sigma-Aldrich, St. Louis, MO) and 1 mg/ml
Figure 6. Role of proteasome inhibition in modulating NF-kB
pathway-mediated expression of Fanconi Anemia (FA)/homol-
ogous recombination (HR) genes. Proteasome inhibition by
bortezomib or PSMA1 knockdown results in an increase in IkBa, which
in turn decreases NF-kB binding to the promoters of FA/HR genes
including FANCD2 and BRCA1. This reduces the availability of these DNA
repair proteins for recruitment to DNA damage sites, resulting in
decreased RAD51 focus formation and HR following induction of DNA
double strand breaks by ionizing radiation.
doi:10.1371/journal.pone.0073710.g006
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Normocin (InvivoGen, San Diego, CA). HEK293T cells were
grown in Gibco DMEM (Life Technologies) in 10% FBS and
1 mg/ml Normocin at 37uC in humidified 5% CO2. U2OS cells
were grown in Gibco McCoy’s 5A (Life Technologies) in 10% FBS
at 37uC in humidified 5% CO2. All cell lines were purchased from
American Type Culture Collection (ATCC, Manassas, VA). 6–8
week old female homozygous CrTac:NCR-Foxn1 (nude) mice
were purchased from Taconic Farms (Germantown, NY).
Whole Genome Pooled shRNA Screen
The screen was performed essentially as previously described for
DLD-1 cells [21]. The Hannon-Elledge whole genome pooled
shRNA library consists of six viral pools each containing
approximately 13,000 different MSCV-PM retroviral shRNA
particles targeting human genes. For each pool, three replicates of
at least 1.36107 cells of A549 or NCI-H460 cells were incubated
with an equivalent number of retroviral colony-forming units in
media containing 8 mg/ml polybrene (Sigma-Aldrich, St. Louis,
MO), for a 1000-fold representation of each shRNA sequence at a
multiplicity-of-infection (MOI) of 1. After selection for stable
integrants using 1 mg/ml puromycin, cells were passaged for a
total of twelve population doublings (PD), at all times maintaining
a minimum of 1.36 107 cells per replicate. Genomic DNA was
extracted from cells harvested both before and after the twelve
population doublings. Half-hairpin shRNA-containing sequences
were amplified by PCR, purified by agarose gel electrophoresis
Figure 7. Combination of proteasome inhibition and radiation enhances tumor control. 106 NCI-H460 cells transfected with doxycycline-
inducible PSMA1 shRNA were injected into the flanks of 6–8 week-old NCr nude mice. Once tumors reached 3 mm diameter (day 0), PSMA1
knockdown was initiated with doxycycline drinking water. One week later, RT was initiated to give a total of five 4 Gy fractions every other day using
a small animal radiation research platform (SARR). (A) Orthogonal images from a cone beam computed tomography (CT) scan, obtained using the
SARRP, of a mouse bearing a subcutaneous xenograft. (B) Correlation of volumetric tumor measurements using the SARRP cone beam CT compared
to traditional calipers. (C) Treatment schema. (D) Mice were subsequently followed until tumors reached 2 cm diameter, animals became moribund or
for 100 days. (E) Kaplan-Meier analyses were performed with pairwise log-rank tests to assess differences in survival. Numbers surviving out of 10
mice per group on day 100 are indicated in brackets. For RT vs. RT+PSMA1 knockdown, log rank P = 0.0003.
doi:10.1371/journal.pone.0073710.g007
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Figure 8. Proteasome inhibition delays DNA repair in vivo. (A) FANCD2 immunofluorescence in 10 Gy irradiated vs. unirradiated NCI-H460
xenografts recovered from mice with or without doxycycline-induced PSMA1 shRNA expression in tumor cells. Bar = 10 mm. (B) c-H2AX
immunohistochemistry in NCI-H460 xenograft tumors with or without doxycycline-induced PSMA1 shRNA knockdown, recovered from mice 1, 6, and
24 hours after 10 Gy irradiation. Bar = 10 mm. (C) Quantification of immunohistochemistry for c-H2AX in (B). Cells with$5 foci were scored as positive
(n.400 cells). All results are mean 6 SEM. P values were calculated using a two-tailed Student’s t test.
doi:10.1371/journal.pone.0073710.g008
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and labeled with Cy5 (PD 0) or Cy3 (PD 12). Competitive
hybridization to custom Agilent microarrays was performed.
For scoring, the mean log2 (Cy3/Cy5) ratio was determined for
each shRNA sequence using triplicate data. Those shRNAs for
which the standard deviation of log2 (Cy3/Cy5) ratios was greater
than the absolute mean log2 (Cy3/Cy5) ratio were excluded from
further analyses to reduce false positive hits. For each gene, one
point was assigned for each different shRNA sequence targeting
that gene for which the mean log2 (Cy3/Cy5) ratio was less than or
equal to 21, representing a decrease in representation of the
shRNA sequence of at least 2-fold during passaging. One half
point was assigned for each shRNA sequence for which the mean
log2 (Cy3/Cy5) ratio was less than or equal to 20.5. A negative
point was assigned for each shRNA sequence for which the mean
log2 (Cy3/Cy5) ratio was greater than or equal to +1, and a
negative half point was assigned for each shRNA sequence for
which the mean log2 (Cy3/Cy5) ratio was greater than or equal to
+0.5, to penalize discordant results among shRNA sequences
targeting a particular gene. Finally, genes were ranked based on
descending total score, with higher rankings given to genes with
equivalent total scores but fewer different shRNA sequences
targeting the gene.
PSMA1 shRNA Inducible Cell Lines
The TRIPZ plasmid containing PSMA1 shRNA sequence
V2THS_170669 was purchased from Thermo Scientific (Rock-
ford, IL). The non-silencing shRNA control (RHS4743, Thermo
Scientific) was also purchased. Lentiviral particles were generated
using the Trans-Lentiviral Packaging Mix (Thermo Scientific) in
HEK293T cells per manufacturer’s protocol. Viral titers were
assessed by serial dilution using U2OS cells. A549 and NCI-H460
cells were infected at a MOI of 1.5. Transfected cells were selected
with puromycin, and individual subclones were tested for
doxycycline-inducible PSMA1 shRNA knockdown via Western
blot.
Proteasome Activity Assay
96-well white, clear bottom polystyrene tissue culture plates
(#3903, Corning, Tewksbury, MA) were seeded with 1000
NSCLC cells in 200 ml media. After 24 hours, media was replaced
with media containing bortezomib, or PSMA1 shRNA was
induced with 1 mg/ml doxycycline. Cells were incubated for up
to 3 days prior to chymotrypsin-like proteasome activity assays
using the Proteasome-Glo cell-based luminescent assay (Promega,
Madison, WI) per manufacturer’s protocol. All results were
normalized to cells treated with DMSO vehicle control for
bortezomib or non-silencing control for RNAi knockdown.
Clonogenic Cell Survival Assay
NSCLC cells were seeded into 6-well tissue culture-treated
dishes (#3516, Corning, Tewksbury, MA) at 10% confluence.
Bortezomib was initiated 24 hours after seeding and continued
during IR initiated 24 hours after bortezomib. IR was given using
a Gammacell 40 Exactor Cs-137 irradiator (Best Theratronics,
Ottawa, Ontario, Canada) in 1 or 2 Gy daily fractions over three
days. Six hours after the final fraction, cells were trypsinized,
counted, and seeded into 10 cm dishes in triplicate to generate
isolated colonies. Once colonies became visible by eye, plates were
stained with 1% crystal violet (Sigma-Aldrich) and colonies of at
least 50 cells were counted by eye.
Apoptosis Assay
NCI-H460 cells were seeded into 6-well tissue culture treated
dishes (Corning) at 10% confluence. Bortezomib was initiated 24
hours after seeding and continued during IR. 2 to 4 Gy IR was
administered 24 hours later using a Gammacell 40 Exactor Cs-137
irradiator (Best Theratronics). Cells were prepped and stained 24
hours later with the FITC Annexin V Apoptosis Detection Kit II
(#556570, BD Biosciences, San Jose, CA) as per manufacturer’s
protocol. Quantification was performed by flow cytometry (BD
LSRFortessa, BD Biosciences, San Jose, CA).
Western Immunoblots
For whole cell lysates, 1 ml ice-cold RIPA buffer [proteasome
inhibitor Complete mini (11 836 153 001, Roche Diagnostics,
Mannheim, Germany), 150 mM NaCl (Sigma-Aldrich), 1.0%
IGEPAL CA-630 (Sigma-Aldrich), 0.5% sodium deoxycholate
(Sigma-Aldrich).01% SDS (Bio-Rad, Hercules, CA), 50 mM Tris,
pH 8.0 (Bio-Rad)] per 107 cells was used. Semi-dry transfer was
performed using the Trans-Blot SD apparatus onto PVDF
membrane (Bio-Rad) per manufacturer’s protocol. Western
Lightning Plus enhanced chemiluminesence substrate (PerkinEl-
mer, Waltham, MA) was used for visualization on Amersham
Hyperfilm (GE Healthcare, Pittsburgh, PA).
Immunofluorescence
Cells were fixed with 4% formaldehyde (Sigma-Aldrich)
followed by ice-cold methanol 6 hours post IR. Slides were
incubated on a rocker at room temperature for 2 hours in blocking
buffer containing 10% normal goat serum and 0.3% Triton X-
100, then incubated in primary antibody overnight followed by
secondary antibody for one hour in antibody buffer containing
PBS, 1% bovine serum albumin and 0.3% Triton X-100).
ProLong Gold antifade reagent with DAPI (Life Technologies,
Grand Island, NY) was used for mounting. An Axio Imager Z1
fluorescence microscope with AxioCam MRc and MRm CCD
cameras (Zeiss, Thornwood, NY) was used for visualization. DNA
damage-inducible foci were counted manually in 100 cells per
sample, with a minimum of 3 replicates.
Comet Assay
Cells were seeded into 6-well plates at 20% confluence.
Bortezomib was initiated 24 hours after seeding and refreshed 1
hour prior to IR the following day. 40 Gy IR was given using a
Gammacell 40 Exactor with cells on ice, and cells were collected 1,
4 or 8 hours after initiation of IR. The OxiSelect Comet Assay Kit
(Cell Biolabs, San Diego, CA) was used per manufacturer’s
protocol, and comets were visualized using an Axio Imager Z1
fluorescence microscope with an AxioCam MRm CCD camera
(Zeiss, Thornwood, NY).
Homologous Recombination (HR) and Non-homologous
End-joining (NHEJ) Assays
Plasmids phprtDRGFP, pCBASce [28] and pEJ [50] were a gift
from Dr. David Weinstock. A549 and NCI-H460 cells were
transfected with phprtDRGFP (for HR assays) or pEJ (for NHEJ
assays) via FuGENE HD (Roche, Indianapolis, IN). Subclones
harboring single stable integrations were selected by Southern blot
as previously described [28]. GFP reporter assays were performed
as previously described [28,50]. Cells were transiently transfected
with pCBASce to induce DNA double strand breaks at I-SceI sites
introduced via phprtDRGFP or pEJ. Cells were treated with
bortezomib starting 24 hours before pCBASce transfection, or
transfected with 25 nM siGENOME PSMA1 siRNA (D-010123-
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05, Thermo Scientific) or AllStars Negative Control siRNA
(Qiagen, Valencia, CA) via Lipofectamine RNAiMAX reagent
(Invitrogen, Carlsbad, CA) 24–48 hours before pCBASce transfec-
tion. After pCBASce transfection, cells were incubated 24–96 hours
prior to quantification of GFP-expressing cells by flow cytometry
(BD LSRFortessa, BD Biosciences, San Jose, CA).
Quantitative RT-PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen) per
manufacturer’s protocol. cDNA was synthesized using the Iscript
cDNA kit (BioRad, Hercules, CA) per manufacturer’s protocol.
Quantitative RT-PCR was performed using BRCA1 and FANCD2
intron-spanning primers (Eurofins MWG Operon, Huntsville, AL)
with SYBR Green (Bio-Rad) master mix; BRCA1: CAA-
CATGCCCACAGATCAAC (forward) and ATGGAAGC-
CATTGTCCTCTG (reverse), FANCD2: ACGGTGCTAGA-
GAGCTGCTT (forward) and
TGTTCTCAGCACACTGGCAT (reverse). Data was normal-
ized using ACTB: TGAAGTGTGACGTGGACATC (forward)
and GGAGGAGCAATGATCTTGAT (reverse).
IkBa Rescue
A549 or NCI-H460 cells were seeded into 6-well tissue culture
dishes and then transfected with 25 nM IkBa siRNA
(#1= si00126826, #2= si03114630, Qiagen) or AllStars Negative
Control siRNA (Qiagen). After 24 hours, bortezomib was added,
and then 24 hours later, cells were treated with 10 Gy IR. Cells
were assayed for viability 24 hours later by the CellTiter-Glo assay
(Promega, Madison, WI).
Mouse Xenograft Experiments
NCI-H460 cells were trypsinized and suspended at 56106 cells/
ml in 0.9% saline. 16106 cells were injected subcutaneously into
the right flanks of NCr nude mice. Tumor formation was assessed
by caliper, with tumor volume determined by 0.56longest
diameter6shortest diameter2. Once tumors reached at least
200 mm3, PSMA1 shRNA knockdown was induced by including
0.5 mg/ml doxycycline in drinking water. In a separate cohort,
0.6 mg/kg bortezomib given intravenously by tail vein was started.
One week later, IR was initiated to give five fractions of 4 Gy up to
three times per week using a small animal radiation research
platform (SARRP) as described below. In the bortezomib cohort,
treatment was administered 1 hour prior to RT. Doxycycline or
bortezomib was discontinued after the final fraction of RT.
Tumors were assessed until they reached 2 cm diameter or
showed necrosis, or mice showed evidence of morbidity, or 100
days after initiation of treatment, whichever came first. Mice were
euthanized with carbon dioxide. For immunofluorescence, tumor
samples were collected immediately and embedded in O.C.T.
(VWR, 4583) in Tissue-tek cryomold (VWR, 4557) plastic
cassettes. Cassettes with sample and O.C.T. were then placed
above liquid nitrogen until frozen and stored at 280uC. For
immunohistochemistry, tumor samples were collected and fixed in
10% formalin acetate (SF99-4, Fischer Scientific) for 24 hours then
stored in 70% ethanol prior to paraffin embedding and sectioning.
c-H2AX (05–636, Millipore, Billerica, MA) staining at a dilution
of 1:20,000 was performed by the Dana-Farber/Harvard Cancer
Center Research Pathology Core. An Axio Imager Z1 fluores-
cence microscope with an AxioCam MRc camera (Zeiss) was used
for visualization. c-H2AX foci were counted manually with a
minimum of 400 cells per sample. For proteasome activity assays,
tumor samples were collected immediately following euthanasia
and snap frozen and stored at280uC. PBS-EDTA buffer was then
added and samples sonicated for 60 seconds. Proteasomal activity
of the lysate was then assessed using the Proteasome-Glo assay
(Promega) per manufacturer’s protocol.
Small Animal Radiation Research Platform (SARRP)
Mice were anesthetized via isoflurane inhalation for the
duration of each treatment. For each treatment, tumors were
visualized using cone beam computed tomography (CT) using
65 kVp and 0.6 mA photons. Tumors were treated using a 1.2 cm
circular collimator selected to give 0.25–0.5 cm margins around
gross tumor, using 220 kVp and 13 mA photons given with a
lateral en face field prescribed to a depth of 5 mm. The SARRP
was calibrated and maintained as previously described [38,39].
Bioinformatics
Affymetrix HG-U133A CEL files and clinical annotation data
from a published microarray dataset [9] were downloaded from
https://array.nci.nih.gov/caarray/project/details.action?project.
experiment.publicIdentifier = jacob-00182. Gene expression sum-
mary values were computed using the Robust Multichip Average
(RMA) [51] method using RMAExpress 1.0.5 obtained from
http://rmaexpress.bmbolstad.com/, using an Entrez gene-centric
custom CDF downloaded from http://brainarray.mbni.med.
umich.edu/Brainarray/Database/CustomCDF/
genomic_curated_CDF.asp. Kaplan-Meier survival analysis was
performed for BRCA1 and RAD51 using SAS JMP 10 Pro (SAS,
Cary, NC). Data on FANCD2 was not available in this dataset.
Statistics
All quantitative data were analyzed and graphs formed using
Prism 6 (Graphpad Software, La Jolla, CA). All differences
between treatment groups were determined via two-tailed
parametric Student’s t test, with a p value ,0.05 viewed as
significant.
Declaration of Ethical Approval
All animal experiments were performed in accordance with a
protocol (11-024) approved by the Dana-Farber Cancer Institute
Animal Care and Use Committee (DFCI ACUC) and in
adherence to the NIH Guide for the Care and Use of Laboratory
Animals.
Supporting Information
Figure S1 Clonogenic survival assay of A549 (left) and
NCI-H460 (right) following single fraction IR and
bortezomib. Marked bars show the percent kill of bortezomib-
treated samples compared to DMSO vehicle control at each IR
dose. All results are mean 6 SEM and normalized to DMSO
vehicle control.
(EPS)
Figure S2 Proteasome inhibition reduces non-homolo-
gous end joining in NSCLC cells. GFP reporter assay for non-
homologous end joining (NHEJ) after proteasome inhibition for 24
hours via bortezomib (right) or PSMA1 siRNA knockdown (left) in
A549 (top) and NCI-H460 (bottom). All results are mean 6 SD
and normalized to DMSO vehicle control (Veh) or scrambled
vector control. P values were calculated using a two-tailed
Student’s t test.
(TIF)
Figure S3 Bortezomib reduces RAD51, FANCD2 and
BRCA1 IR induced foci in A549. These photos show
representative images for the quantified data in Figure 4 of the
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main text; refer to that figure legend for additional details.
Bar = 10 mm.
(TIF)
Figure S4 PSMA1 shRNA reduces RAD51, FANCD2 and
BRCA1 IR induced foci in A549 and NCI-H460. These
photos show representative images for the quantified data in
Figure 4 of the main text; refer to that figure legend for additional
details. Bar = 10 mm.
(TIFF)
Figure S5 Bortezomib does not improve control of
irradiated NSCLC xenografts. 106 NCI-H460 cells were
injected into the flanks of 6–8 week-old NCr nude mice. Once
tumors reached 3 mm diameter (day 0), bortezomib was injected
into the tail vein at 0.6 mg/kg twice per week. One week later, RT
was initiated to give a total of five 4 Gy fractions every other day
using a small animal radiation research platform (SARRP) with
0.6 mg/kg bortezomib given 1 hour prior to RT. Mice were
subsequently followed until tumors reached 2 cm diameter,
animals became moribund or for 100 days.
(TIF)
Figure S6 Chymotrypsin-like proteasome activity in
NSCLC xenografts following bortezomib vs. inducible
PSMA1 shRNA knockdown. Tumors were collected and
frozen 1 hour after the last of three doses of bortezomib given
over one week, or proteasome inhibition via PSMA1 shRNA
knockdown for one week. Control mice were treated with DMSO
(Veh) or non-silencing shRNA tumors. All results are mean 6
SEM.
(EPS)
Figure S7 High BRCA1 and RAD51 gene expression are
each associated with decreased overall survival. Kaplan-
Meier analysis was performed using a published dataset of 442
lung adenocarcinomas [9], comparing survival among patients
with greater than median expression versus less than median
expression of each gene. The log-rank test was performed to assess
for statistically significant differences in overall survival.
(TIF)
Table S1 Mutations in NSCLC cell lines. List of sequenced
DNA mutations in the NSCLC cell lines A549 and NCI-H460
from the Wellcome Trust Sanger Institute Cancer Cell Line
project (http://www.sanger.ac.uk/genetics/CGP/CellLines/).
A549 and NCI-H460 harbor mutations in the majority of the
same oncogenic and tumor suppressor genes, including CDKN2A,
KRAS and STK11.
(XLSX)
Table S2 Whole genome shRNA screen hits in A549 and
NCI-H460. Complete list of whole genome shRNA screen hits in
A549 and NCI-H460. Each of the 1,667 genes was the target of at
least one shRNA sequence whose representation decreased by at
least two-fold during passage in both cell lines. Listed are the
numbers of shRNA sequences in the screen targeting each gene,
and the score for each cell line. To derive the score, one point was
given for each shRNA sequence whose representation decreased
by at least two-fold during passage, and one half point was given
for each sequence whose representation decreased by 20.5 to 1-fold.
One point was subtracted for each shRNA sequence whose
representation increased by at least two-fold during passage, and
one half point was given for each sequence whose representation
increased by 20.5 to 1-fold, to penalize discordant effects.
(XLSX)
Table S3 List of 26 S proteasome genes highlighting
whole genome shRNA screen hits. Each of the highlighted
genes was the target of at least one shRNA sequence whose
representation decreased by at least two-fold during passage in
both cell lines, with the top hit PSMA1 shaded red, strong hits
(.1 shRNA sequence per gene in both cell lines) shaded dark
orange and minor hits (1 shRNA sequence per gene in both cell
lines) shaded light orange. Listed are the numbers of shRNA
sequences in the screen targeting each gene, and the score for each
cell line. To derive the score, one point was given for each shRNA
sequence whose representation decreased by at least two-fold
during passage, and one half point was given for each sequence
whose representation decreased by 20.5 to 1-fold. One point was
subtracted for each shRNA sequence whose representation
increased by at least two-fold during passage, and one half point
was given for each sequence whose representation increased by
20.5 to 1-fold, to penalize discordant effects.
(XLSX)
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